Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy aims to stop daytime accidents in kids

NCT ID NCT06551246

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a combination of two drugs (solifenacin and mirabegron) at low doses works better than a high dose of either drug alone for children aged 5 to 14 with daytime wetting. About 236 children who did not fully respond to low-dose single drugs will be randomly assigned to one of four treatment groups for 18 weeks. The goal is to reduce the number of wet days per week.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 236 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 14 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The participants custody holder(s) must voluntarily sign and date an informed consent prior to initiation of any study specific procedures. 2. Age 5 to 14 years (inclusive) at the time of inclusion. 3. Overactive bladder as per International Children's Continence Society criteria 4. At least 2 daytime urinary incontinence episodes per week 5. Inadequate effect of at least 4 weeks urotherapy (non-pharmacological treatment) 6. No previous treatment with solifenacin, mirabegron or bladder/sphincter botulinum toxin injections 7. No current constipation as per ROME IV criteria or fecal incontinence (laxative treatment is accepted) 8. Per investigator's judgment, the participant can swallow or can learn to swallow study medication Exclusion Criteria: 1. Inability of the patent(s) or legal guardian(s) to understand the Danish written and oral information 2. Known or suspected hypersensitivity to study medication 3. Any contraindication to the use of the study medication 4. Known urogenital anatomical abnormalities affecting lower urinary tract function 5. Known kidney or bladder stones 6. Known diabetes insipidus 7. Ongoing symptomatic urinary tract infection 8. Recurrent urinary tract infection or ongoing prophylactic antibiotic treatment 9. Known QTc prolongation, QTc \>460 ms, or risk of QTc prolongation (hypokalaemia, exercise-induced syncope, or familial long QT syndrome) 10. Other significant electrocardiogram abnormalities 11. Known hypertension 12. ≤3 daily voiding, evaluated by 48-hour frequency-volume chart 13. Uroflowmetry suggestive of other pathology than overactive bladder (staccato-shaped, interrupted-shaped, or plateau-shaped curve) 14. Post-void residual \>50 ml after double voiding 15. Dipstick haematuria (≥2+ erythrocytes) or macroscopic haematuria 16. Pregnancy or breastfeeding 17. Female subjects of childbearing potential 18. Ongoing constipation according to Rome IV-criteria which is intractable to medication or fecal incontinence 19. Inability to swallow study medication 20. Use of any medication during study period, except permitted medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urinary incontinence in children are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Diurnal Enuresis enuresis overactive bladder Urinary Incontinence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Pediatric and Adolescent Medicine, Aalborg University Hospital

    RECRUITING

    Aalborg, Aalborg, 9000, Denmark

  • Department of Pediatric and Adolescent Medicine, Aarhus University Hospital

    RECRUITING

    Aarhus, Aarhus N, 8200, Denmark

  • Department of Pediatric and Adolescent Medicine, Gødstrup Hospital

    RECRUITING

    Herning, Herning, 7400, Denmark

  • Department of Pediatric and Adolescent Medicine, Kolding Hospital

    RECRUITING

    Kolding, Kolding, 6000, Denmark

  • Department of Pediatric and Adolescent medicine, Esbjerg Hospital

    RECRUITING

    Esbjerg, Esbjerg, 6700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.